Signal / field note

Peptide news: reading the next offer

A field note for comparing an announcement with a provider, pharmacy and proposed preparation.

Source desk

Read beyond the headline.

Peptide library

Search the reference entries and follow their sources.

Explore the library →

Semaglutide citations: follow a claim to its evidence

An investigation of what a research reference supports, and where an online review must stop.

Read the analysis →

Tirzepatide citations: trace the comparison behind the claim

How to follow an explanation back to the design and observations it requires.

Read the analysis →

23 guide pages · updated 2026-08-14

Guides

How the drugs work, what the dose ladder asks of you, what it costs, who qualifies, what the side effects mean in practice, how the cold chain works, and how to tell a regulated seller from a risky one.

Guide · start here

Start here: which GLP-1 question are you actually asking?

There are only about six of them, and they lead to different places. This page sorts the 92 reviews, 6 medication pages and everything else on this site by the question that brought you, and states plainly what is not here.

5 sources · updated 2026-08-23

Guide · cost

What GLP-1s actually cost in 2026

The same brand-name drug appears in this research at $149 a month and at $1,599 a month. Here is what explains the difference, and how to work out your real number.

12 sources · updated 2026-08-14

Guide · eligibility

Who qualifies for a GLP-1, and what a real intake asks

Eligibility has a clinical answer and a commercial one. The gap between them is where the risk sits — and a good intake is the one that can turn you down.

14 sources · updated 2026-08-14

Guide · safety

GLP-1 side effects, sorted by what to do about them

Grouped by the action they call for rather than by how often they appear in a footnote — because the useful question is not how common something is, but whether it means calling someone.

5 sources · updated 2026-08-14

Guide · logistics

Shipping, storage and what happens when the box is late

These are cold-chain medicines on a weekly schedule. What each service publishes about getting them to you — and most publish very little.

15 sources · updated 2026-08-14

Guide · payment

Insurance, HSA and FSA for GLP-1s

Most telehealth services in this market cannot take your insurance and say so quietly. Here is which ones can, which confirm HSA and FSA cards work, and what the manufacturer programmes require.

16 sources · updated 2026-08-14

Guide · dosing

GLP-1 microdosing, and what the trials do not say about it

A fast-growing tier of this market sells a fraction of the studied dose at a fraction of the price. Here is who offers it, what it costs, and the one thing every microdose page leaves out.

7 sources · updated 2026-08-15

Guide · supplements

GLP-1 supplements: what the label says, and what the evidence says

A shelf of pills now borrows the name of a drug class it does not belong to. Here is what those products actually claim, what the trials on their ingredients found, and the narrower case where a supplement genuinely helps someone taking the real thing.

12 sources · updated 2026-08-16

Guide · United Kingdom

Why UK GLP-1 pages tell you so much less

A British clinic that will not print its price is not necessarily hiding it. Advertising a prescription-only medicine to the public is against the rules here, and that single fact reshapes what a UK provider is allowed to put on its website.

6 sources · updated 2026-08-16

Guide · litigation

The drugmakers are suing your pharmacy

Novo Nordisk has filed 132 lawsuits and won 44 permanent injunctions against sellers of compounded semaglutide. Eli Lilly has sued the telehealth companies directly. If you buy compounded, the risk to your supply is not clinical — it is legal.

7 sources · updated 2026-08-16

Guide · coverage

The Medicare GLP-1 Bridge, and the four tests you have to pass

From 1 July 2026 some Medicare beneficiaries pay $50 a month for Wegovy, the Zepbound KwikPen or Foundayo. It is the cheapest legitimate route to a brand-name GLP-1 anywhere — and the eligibility rules exclude more people than they let in.

4 sources · updated 2026-08-18

Guide · stopping

What happens when you stop

Every price on this site is a monthly price, and the trials are clear about what a last month looks like. Weight comes back at about 0.8 kg a month on semaglutide or tirzepatide, and the cardiometabolic gains go with it. This is the number to decide on before the first one.

4 sources · updated 2026-08-18

Guide · mechanism

How GLP-1 drugs actually work, and what that explains

One paragraph of pharmacology explains the dose ladder, the nausea, the muscle-loss warnings and the weight regain. It is all in the labels, and the labels are also candid about the parts nobody has established yet.

4 sources · updated 2026-08-23

Guide · dosing

Every dose step, and what to do when you miss one

The escalation ladders are published in full in the prescribing information, and so are the missed-dose rules — which are not the same for the two leading drugs. Getting that difference wrong is one of the few dosing errors a patient can make alone.

5 sources · updated 2026-08-23

Guide · indications

What else these drugs are approved to do

Weight is the indication everyone advertises. It is not the only one on the label — there is now a cardiovascular indication, a sleep-apnoea indication and a liver indication, each with its own evidence and its own caveats, and each with a maintenance dose that may not be the one you were sold.

6 sources · updated 2026-08-23

Guide · before you pay

Thirteen things a GLP-1 service should tell you before you pay

Every review on this site is measured against the same thirteen questions. Across 92 services, not one answers all thirteen — so this is less a checklist of what to expect than a map of where the silences reliably fall.

5 sources · updated 2026-08-23

Guide · risk

How to tell a regulated GLP-1 seller from a risky one

Of the 92 services reviewed here, 13 carry a regulator action on the public record — and 3 of those are the manufacturers themselves. The useful checks are not the ones the scam-warning articles list.

11 sources · updated 2026-08-23

Guide · what to expect

The first year on a GLP-1, in the order things actually happen

The trials that produced the headline numbers ran for 64 to 72 weeks, and the shape of that year is fairly predictable: a long climb on doses nobody stays on, side effects front-loaded into the steps, a maintenance dose somewhere around month four, and a decision at the end that the pricing rarely prepares people for.

5 sources · updated 2026-08-23

Guide · glossary

A GLP-1 glossary, with the marketing words separated out

Some of these terms are pharmacology, some are law, and a few are sales language wearing the costume of the other two. Knowing which is which is most of what it takes to read a sales page in this market.

9 sources · updated 2026-08-23

Guide · interactions

What else you are taking, and why these drugs change it

A medicine that slows the stomach changes how every tablet you swallow is absorbed. The labels quantify some of those effects precisely, and one of them — a contraceptive interaction that applies to tirzepatide and not to semaglutide — is missing from almost every sales page in this market.

3 sources · updated 2026-08-23

Guide · pregnancy

Pregnancy, contraception and the two-month rule

Both labels say weight loss offers no benefit in pregnancy and may cause fetal harm. One of them also says the drug can make your contraceptive pill less reliable. Between those two sentences sits a gap that the services selling these drugs are largely silent about.

2 sources · updated 2026-08-23

Guide · body composition

Muscle loss on a GLP-1, and what the scans actually found

The DXA substudies describe changes in fat and lean tissue during weight loss. Read the absolute changes alongside the proportions and comparison groups, then separate those scan results from muscle strength and everyday function.

7 sources · updated 2026-09-09

Guide · when supply stops

When your supply stops, and what you are owed

Shortages, injunctions, a lapsed subscription or a proposed federal rule can all end a supply mid-course. Restarting is a clinical event rather than an administrative one — and 21 of the 92 services reviewed here publish a refund position at all.

9 sources · updated 2026-08-23

Elsewhere on the site